Skip to Content

Eptinezumab Dosage

Medically reviewed by Drugs.com. Last updated on March 25, 2020.

Applies to the following strengths: 100 mg/mL

Usual Adult Dose for Migraine Prophylaxis

Initial dose: 100 mg via IV infusion every 3 months
Maintenance dose: 100 mg or 300 mg via IV infusion every 3 months.

Comments:
-Some patients may benefit from the higher dose (300 mg every 3 months).
-See administration advice for infusion administration instructions.

Use: For the preventative treatment of migraine.

Renal Dose Adjustments

No adjustment recommended

Liver Dose Adjustments

No adjustment recommended

Precautions

CONTRAINDICATIONS:
-Serious hypersensitivity to active substance or any product excipients; reactions have included angioedema

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-For IV infusion by a healthcare provider every 3 months
-Infuse over approximately 30 minutes
-Use an IV infusion set with a 0.2 or 0.22 micron in-line or add-on filter; once infusion is complete, flush line with 20 mL of sodium chloride 0.9%

Storage requirements:
-Prior to use: Refrigerate vials (2C to 8C [36F to 46F]) in the original carton to protect from light; do not freeze or shake
-Store diluted solution at room temperature (20C to 25C [68F to 77F]); infuse solution within 8 hours of preparation

Reconstitution/preparation techniques:
-Dilute prior to administration
-Infusion bags should be made of polyvinyl chloride, polyethylene, or polyolefin
-Withdraw drug from vial and inject into 100 mL bag of 0.9% sodium chloride; gently invert solution to mix, do not shake

IV compatibility: No other medications should be administered through infusion set or mixed with this drug

General:
-Efficacy studies excluded patients with a history of cardiovascular disease (hypertension, ischemic heart disease), neurological disease, or cerebrovascular disease.

Patient advice:
-Patients should be instructed to read the US FDA-approved patient labeling (Patient Information).
-Patients should be instructed to contact their healthcare provider if they experience signs or symptoms of an allergic reaction.
-Patients should be advised to speak with their healthcare provider if they become pregnant or plan to become pregnant, are breastfeeding or plan to breastfeed during therapy.

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

More about eptinezumab

Consumer resources

Other brands: Vyepti

Professional resources

Related treatment guides